Management of metabolic syndrome in children and adolescents

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 6, 2011, Pages 455-466

  Pacifico, L ^a   Anania, C ^a   Martino, F ^a   Poggiogalle, E ^b   Chiarelli, F ^b   Arca, M ^a   Chiesa, C ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c CNR   (Italy)

Author keywords

Children; Metabolic syndrome; Review; Treatment

Indexed keywords

ANTIDIABETIC AGENT; ANTIOXIDANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN;

ADOLESCENT; BLOOD; CARDIOVASCULAR DISEASE; CHILD; DIET; EXERCISE; FATTY LIVER; HUMAN; HYPERTENSION; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; REVIEW;

ADOLESCENT; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; FATTY LIVER; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; LIFE STYLE; METABOLIC SYNDROME X; METFORMIN; OBESITY; PREVALENCE;

EID: 79955950803     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.01.011     Document Type: Review

References (76)

1. Cook S., Weitzman M., Auinger P., Nguyen M., Dietz W.H. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003, 157:821-827.
2. Kotronen A., Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38.
3. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-1350.
4. Steinberger J., Daniels S.R., Eckel R.H., Hayman L., Lustig R.H., McCrindle B., et al. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009, 119:628-647.
5. Zimmet P., Alberti K.G., Kaufmann F., Tajima N., Silink M., Arslanian S., et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes 2007, 8:299-306.
6. Goodman E., Daniels S.R., Meigs J.B., Dolan L.M. Instability in the diagnosis of metabolic syndrome in adolescents. Circulation 2007, 115:2316-2322.
7. D'Adamo E., Marcovecchio M.L., Giannini C., Capanna R., Impicciatore M., Chiarelli F., et al. The possible role of liver steatosis in defining metabolic syndrome in prepubertal children. Metabolism 2010, 59:671-676.
8. Bacha F., Saad R., Gungor N., Janosky J., Arslanian S.A. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab 2003, 88:2534-2540.
9. Williams C.L., Hayman L.L., Daniels S.R., Robinson T.N., Steinberger J., Paridon S., et al. Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002, 106:143-160.
10. Barbeau P., Johnson M.H., Howe C.A., Allison J., Davis C.L., Gutin B., et al. Ten months of exercise improves general and visceral adiposity, bone, and fitness in black girls. Obesity 2007, 15:2077-2085.
11. Kim Y., Lee S. Physical activity and abdominal obesity in youth. Appl Physiol Nutr Metab 2009, 34:571-581.
12. Daniels S.R., Arnett D.K., Eckel R.H., Gidding S.S., Hayman L.L., Kumanyika S., et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005, 111:1999-2012.
13. Sinaiko A.R., Donahue R.P., Jacobs D.R., Prineas R.J. Relation of weight and rate of increase in weight during childhood and adolescence to body size, blood pressure, fasting insulin, and lipids in young adults. The Minneapolis Children's Blood Pressure Study. Circulation 1999, 99:1471-1476.
14. Kraus W.E., Houmard J.A., Duscha B.D., Knetzger K.J., Wharton M.B., McCartney J.S., et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002, 347:1483-1492.
15. Ylitalo V.M. Treatment of obese schoolchildren. Klin Padiatr 1982, 194:310-314.
16. Knip M., Nuutinen O. Long-term effects of weight reduction on serum lipids and plasma insulin in obese children. Am J Clin Nutr 1993, 57:490-493.
17. Caranti D.A., de Mello M.T., Prado W.L., Tock L., Siqueira K.O., de Piano A., et al. Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents. Metabolism 2007, 56:1293-1300.
18. Reinehr T., Kleber M., Toschke A.M. Lifestyle intervention in obese children is associated with a decrease of the metabolic syndrome prevalence. Atherosclerosis 2009, 207:174-180.
19. Harden K.A., Cowan P.A., Velasquez-Mieyer P., Patton S.B. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. J Am Acad Nurse Pract 2007, 19:368-377.
20. Monzavi R., Dreimane D., Geffner M.E., Braun S., Conrad B., Klier M., et al. Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention. Pediatrics 2006, 117:e1111-e1118.
21. Wickham E.P., Stern M., Evans R.K., Bryan D.L., Moskowitz W.B., Clore J.N., et al. Prevalence of the metabolic syndrome among obese adolescents enrolled in a multidisciplinary weight management program: clinical correlates and response to treatment. Metab Syndr Relat Disord 2009, 7:179-186.
22. Gidding S.S., Dennison B.A., Birch L.L., Daniels S.R., Gillman M.W., Lichtenstein A.H., et al. Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. Circulation 2005, 112:2061-2075.
23. Zappalla F.R., Gidding S.S. Lipid management in children. Endocrinol Metab Clin North Am 2009, 38:171-183.
24. McCrindle B.W., Urbina E.M., Dennison B.A., Jacobson M.S., Steinberger J., Rocchini A.P., et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007, 115:1948-1967.
25. Sinha R., Fisch G., Teague B., Tamborlane W.V., Banyas B., Allen K., et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002, 346:802-810.
26. Steffen L.M., Jacobs D.R., Murtaugh M.A., Moran A., Steinberger J., Hong C.P., et al. Whole grain intake is associated with lower body mass and greater insulin sensitivity among adolescents. Am J Epidemiol 2003, 158:243-250.
27. Delzenne N.M., Cani P.D. A place for dietary fibre in the management of the metabolic syndrome. Curr Opin Clin Nutr Metab Care 2005, 8:636-640.
28. Morrison J.A., Glueck C.J., Horn P.S., Schreiber G.B., Wang P. Pre-teen insulin resistance predicts weight gain, impaired fasting glucose, and type 2 diabetes at age 18-19 y: a 10-y prospective study of black and white girls. Am J Clin Nutr 2008, 88:778-788.
29. Andersen L.B., Harro M., Sardinha L.B., Froberg K., Ekelund U., Brage S., et al. Physical activity and clustered cardiovascular risk in children: a cross-sectional study (The European Youth Heart Study). Lancet 2006, 368:299-304.
30. Raitakari O.T., Porkka K.V., Taimela S., Telama R., Räsänen L., Viikari J.S. Effects of persistent physical activity and inactivity on coronary risk factors in children and young adults. The Cardiovascular Risk in Young Finns Study. Am J Epidemiol 1994, 140:195-205.
31. Ode K.L., Frohnert B.I., Nathan B.M. Identification and treatment of metabolic complications in pediatric obesity. Rev Endocr Metab Disord 2009, 10:167-188.
32. Carrel A.L., Clark R.R., Peterson S.E., Nemeth B.A., Sullivan J., Allen D.B. Improvement of fitness, body composition, and insulin sensitivity in overweight children in a school-based exercise program: a randomized, controlled study. Arch Pediatr Adolesc Med 2005, 159:963-968.
33. Savoye M., Shaw M., Dziura J., Tamborlane W.V., Rose P., Guandalini C., et al. Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA 2007, 297:2697-2704.
34. Nathan D.M., Davidson M.B., DeFronzo R.A., Heine R.J., Henry R.R., Pratley R., et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007, 30:753-759.
35. Srinivasan S., Ambler G.R., Baur L.A., Garnett S.P., Tepsa M., Yap F., et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006, 91:2074-2080.
36. Freemark M., Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001, 107:E55.
37. Kay J.P., Alemzadeh R., Langley G., D'Angelo L., Smith P., Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metab Clin Exp 2001, 50:1457-1461.
38. Love-Osborne K., Sheeder J., Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008, 152:817-822.
39. Burgert T.S., Duran E.J., Goldberg-Gell R., Dziura J., Yeckel C.W., Katz S., et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes 2008, 9:567-576.
40. Atabek M.E., Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2008, 21:339-348.
41. Clarson C.L., Mahmud F.H., Baker J.E., Clark H.E., Mckay W.M., Schauteet V.D., et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine 2009, 36:141-146.
42. Wilson D.M., Abrams S.H., Aye T., Lee P.D., Lenders C., Lustig R.H., et al. Metformin extended release treatment of adolescent obesity. A 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med 2010, 164:116-123.
43. Wiegand S., L'Allemand D., Hübel H., Krude H., Bürmann M., Martus P., et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol 2010, 163:585-592.
44. Sorof J.M., Lai D., Turner J., Poffenbarger T., Portman R.J. Overweight, ethnicity, and the prevalence of hypertension in school- aged children. Pediatrics 2004, 113:475-482.
45. Reinehr T., Andler W. Changes in the atherogenic risk factor profile according to degree of weight loss. Arch Dis Child 2004, 89:419-422.
46. Puri M., Flynn J.T. Management of hypertension in children and adolescents with the metabolic syndrome. J Cardiometab Syndr 2006, 1:259-268.
47. He F.J., MacGregor G.A. Importance of salt in determining blood pressure in children: meta-analysis of controlled trials. Hypertension 2006, 48:861-869.
48. Kelley G.A., Kelley K.S., Tran Z.V. The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials. Prev Cardiol 2003, 6:8-16.
49. Soffer B., Zhang Z., Miller K., Vogt A., Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 2003, 16:795-800.
50. Wells T., Frame V., Soffer B., Shaw W., Zhang Z., Herrera P., et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 2002, 42:870-880.
51. Li J.S., Berezny K., Kilaru R., Portman R., Hogg R., Jenkins R.D., et al. Is the extrapolated adult dose of fosinipril safe and effective in treating hypertensive children?. Hypertension 2004, 44:289-293.
52. Shahinfar S., Cano F., Soffer B.A., Ahmed T., Santoro E.P., Zhang Z., et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 2005, 18:183-190.
53. Trachtman H., Hainer J.W., Sugg J., Teng R., Sorof J.M., Radcliffe J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens 2008, 10:743-750.
54. Flynn J.T., Meyers K.E., Neto J.P., de Paula Meneses R., Zurowska A., Bagga A., et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension 2008, 52:222-228.
55. Flynn J.T., Newburger J.W., Daniels S.R., Sanders S.P., Portman R.J., Hogg R.J., et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 2004, 145:353-359.
56. Trachtman H., Frank R., Mahan J.D., Portman R., Restaino I., Matoo T.K., et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003, 18:548-553.
57. Sorof J.M., Cargo P., Graepel J., Humphrey D., King E., Rolf C., et al. Beta-Blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol 2002, 17:345-350.
58. Hall J.E. The kidney, hypertension, and obesity. Hypertension 2003, 41:625-633.
59. Herder S.D., Weber E., Winkemann A., Herder C., Morck H. Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents. Pediatr Nephrol 2010, 25:801-811.
60. Gillespie E.L., White C.M., Kardas M., Lindberg M., Coleman C.I. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28:2261-2266.
61. Loomba R., Sirlin C.B., Schwimmer J.B., Lavine J.E. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009, 50:1282-1293.
62. Pacifico L., Poggiogalle E., Cantisani V., Menichini G., Ricci P., Ferraro F., et al. Pediatric nonalcoholic fatty liver disease: a clinical and laboratory challenge. World J Hepatol 2010, 2:275-288.
63. Petersen K.F., Dufour S., Befroy D., Lehrke M., Hendler R.E., Shulman G.I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54:603-608.
64. Nobili V., Manco M., Devito R., Di Ciommo V., Comparcola D., Sartorelli M.R., et al. Lifestyle interevention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008, 48:119-128.
65. Ebbeling C.B., Leidig M.M., Sinclair K.B., Hangen J.P., Ludwig D.S. A reduced-glycemic load diet in the treatment of adolescent obesity. Arch Pediatr Adolesc Med 2003, 157:773-779.
66. Benjaminov O., Beglaibter N., Gindy L., Spivak H., Singer P., Wienberg M., et al. The effect of a low-carbohydrate diet on the nonalcoholic fatty liver in morbidly obese patients before bariatric surgery. Surg Endosc 2007, 21:1423-1427.
67. Reinehr T., Schmidt C., Toschke A.M., Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child 2009, 94:437-442.
68. Lavine J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000, 136:734-738.
69. Kugelmas M., Hill D.B., Vivian B., Marsano L., McClain C.J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003, 38:413-419.
70. Vajro P., Mandato C., Franzese A., Ciccimarra E., Lucariello S., Savoia M., et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004, 38:48-55.
71. Nobili V., Marcellini M., Devito R., Ciampalini P., Piemonte F., Comparcola D., et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006, 44:458-465.
72. Wang C.-L., Liang L., Fu J.-F., Zou C.C., Hong F., Xue J.Z., et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008, 14:1598-1602.
73. Vajro P., Franzese A., Valerio G., Iannucci M.P., Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000, 136:739-743.
74. Schwimmer J.B., Middleton M.S., Deutsch R., Lavine J.E. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005, 21:871-879.
75. Nobili V., Manco M., Ciampalini P., Alisi A., Devito R., Bugianesi E., et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008, 30:1168-1176.
76. Lavine J.E., Schwimmer J.B., Molleston J.P., Scheimann A.O., Murray K.F., Abrams S.H., et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010, 31:62-70.